Avacta Share Discussion Threads

[ffp] 18/4/2018 20:16

Liked that

[dickdastardly1] 18/4/2018 20:15

I agree with Poacher: Professor Smith likes to talk the talk on the webcam, burn the cash but can't do deals whatever the technology. As they say, you can take the academic out the lab but you can't take the lab out the academic! Look like another fund raising is on the way and the cycle starts all over again. DD

[lantanatony] 17/4/2018 14:46

Crazy!
Avacta raised their funding at £1,20.
What do you think those investors think ?

[escapetohome] 17/4/2018 12:49

You wouldnt think so at all.

I think it should be recognised that some progress has been made.

Perhaps not financially, but sadly some investors are churning out the negative record, solely because they bought at much higher prices!!!!!!!!!!!

[lantanatony] 17/4/2018 12:41

What's your point?
We know all about this stuff!

[escapetohome] 16/4/2018 22:57

packages.


-- Solid progress with partners:
-- Positive outcome of initial trial with Glythera Ltd. leading to a new drug development partnership for Affimer drug conjugates.

-- Research collaboration with FIT Biotech Oy established to demonstrate effectiveness of the combined technologies for gene delivered Affimer therapeutics: data expected shortly.

-- Moderna research collaboration has a natural three-year termination date at the end of May 2018 and the Group anticipates delivering Affimer assets to Moderna for development by that date or under an extension to the agreement.

-- Continuing collaboration with Memorial Sloan Kettering Cancer Center CAR-T on proof-of-concept study: the Group continues to work to generate Affimer binders to the target of interest.

-- Collaboration established with OncoSec (NASDAQ: ONCS) on innovative gene delivery of therapeutic Affimers: third partnership to explore gene delivery with Affimers reflects significant interest received for this application.

[escapetohome] 16/4/2018 22:56

Excellent progress with second immuno-oncology programme, a LAG3 blockade, which can be combined with PD-L1 for improved efficacy.

-- Discovery programme continues to deliver a pipeline of Affimer binders to other important immuno-oncology targets for future partnering or development.

-- Very positive pharmacokinetic data obtained in mouse for Affimer XT(TM) half-life extension platform.

-- Continued platform validation and de-risking through completion of a number of in-vitro data packages.

[spekky] 16/4/2018 22:33

Bearing in mind this is the only real financial commitment.....

"- Moderna research collaboration has a natural three-year termination date at the end of May 2018 and the Group anticipates delivering Affimer assets to Moderna for development by that date or under an extension to the agreemen "

What happens if no extension? It's game over imho.

For clarity,I would like to take a small punt here but will not do so without the Moderna continuity.

[escapetohome] 16/4/2018 12:37

And yet the comments in the report only speak of success and achievement!!

[poacher45] 16/4/2018 09:46

Not quite spekky the losses just keep going up and up. There are no financial controls.

[spekky] 16/4/2018 08:01

I sold here a couple of years ago but can't seem to take my mind off it.....however,it still seems to have been the right decision....these latest results read almost the same as ones from five years ago.....boring and repetitive.

[lantanatony] 14/4/2018 21:14

Why do you think the Animal Division has any value?

[escapetohome] 14/4/2018 07:24

No , sell of the animal division, to fund the other, do something showing some business acumen.

Ha ha.

[jackg3] 14/4/2018 03:38

By "remedy it" do you mean raise more cash and buy yet another academic technology from Leeds University for Prof. Smith to play with?

[escapetohome] 13/4/2018 19:00

An unacceptable performance Avacta, remedy it and soon please.

[the drewster] 12/4/2018 16:03

I agree the message is getting a little stale without commercial successes to validate it all. We need an update on deals!!

[catch007] 12/4/2018 15:48

I was attracted by the science and potential of avacta however my initial purchase price at 70p seems a long way off now. The biotech capital interviews and updates are all positive yet the share slide continues. I bought a few more today to average down ...not usually a great idea to catch a falling knife however if the affirmer is confirmed then it may prove to be a decent buy. GLA

[escapetohome] 11/4/2018 10:40

Come on now avacta , you keep spouting the talk, how about living up to it.

And perhaps next time a little coordination, try having an investor evening when there is a news item to report on.

[lantanatony] 11/4/2018 08:48

The same old presentation but a little less positive!
Where did Dr Smith get a 40 million valuation from on the 5th?
This presentation has been done to death and is just not working.

[the drewster] 09/4/2018 08:30

It's available for download on the website.

[escapetohome] 07/4/2018 19:14

Did anyone see the presentation ?

Thanks in advance!!

[lantanatony] 29/3/2018 09:42

We need some proper Brokers,capable of supporting the share price.
Let's also hope IP Group are the seller as we need them to reduce their influence.
But most of all we need a deal with revenue attached.

[danatkins] 28/3/2018 19:48

Escapetohome well done for getting out BE. Let's hope for an upward move soon. Need some news soon. This stock has large swings in both directions but this slide has gone further than I'd like. GL

[escapetohome] 28/3/2018 19:23

Yes i did make a purchase nearly 3000 shares bought by me today. I sold my small holding here , breaking even, ive now decided this represents an atractive level to get back in.

Director buy above 40p

ATTRACTIVE ATTRACTIVE ATTRACTIVE ATTRACTIVE ATTRACTIVE BUY